BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Roskoski R Jr. Janus kinase (JAK) inhibitors in the treatment of neoplastic and inflammatory disorders. Pharmacol Res 2022;183:106362. [PMID: 35878738 DOI: 10.1016/j.phrs.2022.106362] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Roskoski R. Properties of FDA-approved Small Molecule Protein Kinase Inhibitors: A 2023 Update. Pharmacological Research 2022. [DOI: 10.1016/j.phrs.2022.106552] [Reference Citation Analysis]
2 Shash H. Non-Transfusion-Dependent Thalassemia: A Panoramic Review. Medicina (Kaunas) 2022;58:1496. [PMID: 36295656 DOI: 10.3390/medicina58101496] [Reference Citation Analysis]
3 Li X, Jiang W, Dong S, Li W, Zhu W, Zhou W. STAT3 Inhibitors: A Novel Insight for Anticancer Therapy of Pancreatic Cancer. Biomolecules 2022;12:1450. [PMID: 36291659 DOI: 10.3390/biom12101450] [Reference Citation Analysis]
4 Sabnis RW. Boron-Containing Pyrazole Compounds as JAK Inhibitors for Treating Inflammation, Autoimmune Diseases, and Cancer. ACS Med Chem Lett . [DOI: 10.1021/acsmedchemlett.2c00407] [Reference Citation Analysis]